Positive head-to-head results for GSK’s umeclidinium in COPD
21 October 2015 | By Victoria White
The results come from two head-to-head studies directly comparing the efficacy and safety of umeclidinium to two available bronchodilator treatments...
List view / Grid view
21 October 2015 | By Victoria White
The results come from two head-to-head studies directly comparing the efficacy and safety of umeclidinium to two available bronchodilator treatments...
In this Informatics In-Depth Focus: Informatics in 2025, Methods for the detection of drug-drug interactions in text & Computational approaches to mutagenicity assessments of impurities: in silico methods...
Historically, the regulation and control of medicinal products has relied on national and supranational guidelines covering good manufacturing practice (GMP). However, the quality of these medicinal products can be adversely affected by a lack of adequate control over the myriad activities that occur during the distribution process. In addition, the…
Maintaining the security of the supply chain for drug products is a significant responsibility to ensure the sustained availability of safe medicines...
In this free-to-view LC-MS in-depth focus, we delve into the world of glycans, and how their natural complexity necessitates sophisticated sequencing techniques, while another article aims to demonstrate the versatility of LC-MS and the ease with which it can be combined with a variety of MS systems, focusing particularly on…
The World Health Organisation (WHO) in 2010 described counterfeit medicines as those which are “Deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active…
11 February 2015 | By GlobalData
Following a less than flattering financial performance in 2014, GlaxoSmithKline plc is realigning its operating structure with its corporate objectives and cashing in on its assets in the process, as the company seeks to drive up external investments and deliver stronger shareholder returns in the long term, says an analyst…
23 January 2015 | By GlaxoSmithKline
GSK has announced that the first batch of its candidate Ebola vaccine is being shipped to west Africa...
This free-to-view Screening In-Depth Focus is packed with articles that will give you a greater understanding of interesting topics such as the identification of compounds that protect against free radicals, advancements in sandwich immunoassay techniques and hit validation and optimisation...
Cocrystals can help to address the manufacturability (flow, compaction, processability) as well as solubility/dissolution,hygroscopicity and stability properties of an active pharmaceutical ingredient (API).
9 December 2014 | By GSK
GSK presented data at the British Thoracic Society meeting from a systematic analysis of 25 randomised control studies (RCTs), including a meta-analysis of three key efficacy outcomes, which explored the potential impact of the particle size of different ICS-containing asthma medicines, including Seretide/Advair (salmeterol/fluticasone proprionate) on patient outcomes...
17 November 2014 | By Medidata
Joint initiative evaluates impact of mHealth and cloud-based technologies on patient engagement, data quality and operational efficiencies in clinical trials...
14 November 2014 | By GlaxoSmithKline
GSK launched the first call for proposals for its Africa NCD Open Lab, to support much-needed scientific research into non-communicable diseases (NCDs) in Africa...
Crystallography is the science underpinning crystallisation, as well as a basic understanding of atomic arrangement within solids and their resulting structures. The United Nations announced that 2014 would be the International Year of Crystallography (IYCr2014). IYCr2014 commemorates the 100th anniversary of X-ray diffraction according to Bragg’s Law (celebrated by the…
24 October 2014 | By GlaxoSmithKline
GSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share...